Within a few supervised sessions paired with talk therapy, MDMA briefly reduces fear and opens emotional processing, helping some people with severe, long-resistant trauma. Benefits for related mood and relationships are promising but less settled; longevity effects remain speculative. Short-term dangers include raised blood pressure and heart rate and difficult emotional reactions. (Full Review)

Protocol

Dose

80–120 mg oral

Optional 40–60 mg top-up 1.5–2 h later

Course

2–3 monthly sessions

Preparatory and integration therapy sessions around dosing

Session

6–8 hours

Two-therapist team, calm room

Time to effect

Trauma symptom improvement

Weeks to months

Assessed over weeks to months after treatment

Durability of benefit

Months to a year+

Trauma benefits can persist after only a few sessions

Acute onset

30–60 min

Drug effects begin after oral dose; last 3–6 hours

Benefits

High: Reduced chronic post-traumatic stress symptoms

Medium: Relief of co-occurring depression and anxiety; deepened engagement in psychotherapy

Low: Reduced problematic alcohol and substance use; improved social comfort in autistic adults; enhanced social connection and empathy

Speculative: Neuroplasticity and brain-derived neurotrophic factor signaling; reduced lifetime stress load and healthspan; relief of fibromyalgia and chronic pain

Contraindications

Monoamine oxidase inhibitors (phenelzine, tranylcypromine, linezolid)

Serotonergic antidepressants, same session (SSRIs, SNRIs)

Uncontrolled hypertension, significant cardiovascular or cerebrovascular disease, serious arrhythmia, recent heart attack (within 90 days)

Severe hepatic impairment (Child-Pugh Class C), advanced kidney disease

Pregnancy and breastfeeding

Personal history of psychotic disorders

Key Interactions

Strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, ritonavir)

Other stimulants and sympathomimetics (prescription amphetamines, pseudoephedrine)

Other serotonergic agents (dextromethorphan)

Serotonergic and stimulant supplements (St. John's Wort, 5-HTP, L-Tryptophan, high-dose caffeine, yohimbine)

Lithium and tramadol

Alcohol and other depressants

Risk & Side Effects

High: Acute cardiovascular strain; common short-term physical and psychological effects

Medium: Low blood sodium; transient worsening of mood or suicidal thoughts

Low: Serotonergic neurotoxicity; liver injury; dangerous overheating

Speculative: Lasting cognitive impairment from therapeutic use; persistent perceptual or psychotic symptoms

Monitoring

Marker	Target	Why
Blood pressure	< 120/80 mmHg at rest	Screens for and tracks the acute pressure surge
Heart rate & rhythm	60–80 bpm resting; normal ECG	Detects arrhythmia risk and tracks acute stimulation
Serum sodium	138–142 mmol/L	Flags baseline risk for hyponatremia
Liver enzymes (ALT/AST)	ALT/AST < 25 U/L	Screens for hepatic vulnerability and injury
Kidney function (eGFR)	> 90 mL/min/1.73m²	Assesses reserve against heat- and muscle-related injury
PTSD symptom score (CAPS-5)	Below diagnostic threshold; lower is better	Defines therapeutic success and tracks response

Cadence: Vital signs continuously during dosing; symptom scales at baseline and after each session; metabolic labs before the course and as clinically indicated; psychiatric follow-up over the ensuing months

Qualitative Assessment

Emotional regulation: reduced hypervigilance, fewer intrusive memories, greater sense of safety
Sleep quality: fewer nightmares and more restorative sleep
Relationships and engagement: improved closeness, trust, and willingness to participate
Mood and outlook: lifting of depressive symptoms and renewed sense of agency

MDMA for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment